u/crp_curious

my hs-CRP halved before the scale moved much, which is the sort of observation i have learned to file as "interesting to me, evidence of nothing". edit: this thread is a good model for that distinction.

the trend across lots is worth more than any single figure

Four pharmacies, four prices, same product, same month. The spread was larger than I expected and none of them were the headline offer.

a result with no batch number is about a vial nobody can identify

Date of analysis anchors the result to a manufacturing period. A two-year-old result is evidence about two years ago and should be read that way.

BMI thresholds vary by ICB and by year

Right, and a point or two between services is ordinary. It is agreement, and every month somebody posts it as a scandal.

the same name covers several different molecules in this space

Which exact molecule? That name covers more than one.

I would not treat catalogue breadth as a quality signal.

Adding the practical question — stocked or made to order, and what is the lead time.

Independent result added to the log — there are very few on that compound.

Agreed — and the naming problem is worse than most people here realise.

Small fix — that is the Scottish pathway. The post is asking about England and the answer is different.

NHS pathway or private prescription?

GP said no and specialist said yes is a very common sequence

Right, and a point or two between services is ordinary. It is agreement, and every month somebody posts it as a scandal.

BCH came back 98.3% on a claimed 98.0%, which is agreement not a discrepancy

Careful, that pricing figure is a headline offer with conditions attached rather than the actual monthly cost.

GP said no in the spring, specialist said yes eighteen months later. Same person, same numbers.

Careful, that pricing figure is a headline offer with conditions attached rather than the actual monthly cost.

On the thin testing history in this board, and what to do about it.

Most of the compounds discussed here have a handful of independent results across the entire site, and several have none. That is a fact about how few members have paid for testing, not a judgement about the material.

What follows: buy small, test identity first for anything unusual, and post the result even when it is unremarkable. The vendor source pages are built from exactly these submissions, and the compounds with the thinnest coverage are the ones where one more entry changes the picture most. Research material is not approved for human use, so what this board can usefully build is an analytical record.

Which nation, and which ICB if you are in England?

That reading assumes area percent and net peptide content are the same number. They are not, and the report says which it is.

Push back: three tests on one lot is one lot. It tells you about that lot and almost nothing about the next one.

Kept every report as a PDF with the batch in the filename. Two years in, it is the most useful folder I own.

the same name covers several different molecules in this space

Careful — that is a claim about efficacy and there is essentially no human evidence behind it.

a result with no batch number is about a vial nobody can identify

area percent unless the report says otherwise

The two routes, described separately, because mixing them is where most of the confusion here starts.

The NHS route in England runs through specialist weight management services commissioned by your ICB. Criteria, waiting times and what happens at discharge are all local decisions, which is why a confident answer from somebody in a different area may be wrong for you.

The private route is an independent transaction: a consultation, a prescription and a pharmacy price. It does not affect your position on any NHS list and it is not a shortcut through one. Both are legitimate; they are simply not the same pathway and they do not connect.

Cosigning on saying who paid. It is the whole basis on which this log is worth anything.

Fourth lot from the same supplier in the log now and the band has been tight the whole way.

Agreed — and two services on one batch is the strongest thing any of us can produce individually.

net peptide content if the report gives it, and say which you are quoting

Net peptide content accounts for counterion, water and residual solvent. On some of these compounds the gap between purity and net content is substantial and entirely honest.

Same. Net peptide content is where the difference between the label and the vial actually shows up.

Scotland, Wales and Northern Ireland have their own arrangements.

omar_eriksen is right that the two routes are separate. A private prescription does not move you up the list.